GLP-1 medicines have become widely known for helping people with type 2 diabetes control blood sugar and lose weight.
Now, a large study from UCLA Health suggests these medications may have another possible benefit. People with type 2 diabetes who started a GLP-1 drug had a lower risk of serious fractures than those who started another type of diabetes medicine.
The finding is important because bone health can be a major concern for people with type 2 diabetes, especially as they grow older. Diabetes can affect much more than blood sugar. Over time, it can damage blood vessels, nerves, kidneys, eyes, and other parts of the body, and it is also linked to an increased risk of some fractures.
The study focused on fragility fractures. These are broken bones caused by relatively minor accidents, such as falling from standing height. In a person with healthy, strong bones, the same fall might not normally cause a fracture.
Fragility fractures become more common with age and can have serious consequences. Hip fractures are particularly dangerous for older adults because they may require surgery, long hospital stays, and months of rehabilitation. Some people never fully regain their previous independence after a major hip fracture.
Researchers have been interested in how GLP-1 receptor agonists affect bones because the medicines can produce substantial weight loss. These drugs copy the effects of a natural hormone involved in blood sugar control, digestion, and appetite. Depending on the medication and patient, they can improve blood sugar while also helping people eat less and lose weight.
Weight loss has many health benefits for people with obesity, but rapid or substantial weight loss can sometimes be accompanied by loss of muscle and bone mass. That raised a question for doctors: could the growing use of GLP-1 medicines unintentionally make bones weaker and increase fractures?
To investigate, UCLA Health researchers examined electronic health records from nearly 134,000 adults in the United States. The participants were between ages 50 and 90 and had type 2 diabetes. Rather than studying people already taking the drugs for years, the researchers compared patients who were newly starting different diabetes treatments.
One group began treatment with a GLP-1 receptor agonist. The comparison group started DPP-4 inhibitors, another class of medicines used to lower blood sugar in type 2 diabetes. Researchers then examined fracture outcomes over a three-year period.
The results were reassuring. People who started GLP-1 medicines had a 21% lower risk of fragility fractures compared with people who started DPP-4 inhibitors. The largest reductions were seen in fractures involving the hip, femur, and spine.
These areas matter because fractures there can cause severe disability. The femur is the large bone in the thigh, while spinal fractures can cause pain, loss of height, and problems with movement. Preventing fractures in these locations could therefore have an important effect on quality of life.
The researchers also conducted a separate analysis involving people without diabetes. The reduced fracture risk was associated specifically with participants who had type 2 diabetes when compared with a matched group without the disease.
This suggests that the relationship may be connected in some way to diabetes or its treatment rather than representing a general bone-protective effect for everyone.
Exactly why GLP-1 medicines might be linked to fewer fractures is not yet clear. Better blood sugar control could potentially help, and weight loss may improve mobility or reduce some health risks. There may also be direct or indirect effects on bone metabolism, inflammation, muscle health, or the likelihood of falling, but these possibilities require further research.
Dr. Christopher Hamad explained that studying fractures presents a challenge because they are relatively uncommon events. Small clinical studies may therefore include too few fractures to detect a reliable difference between treatments. Having health information from more than 133,000 patients gave the UCLA team greater ability to identify patterns.
The study was published in JAMA Network Open, a peer-reviewed medical journal. Its large sample is an important strength, particularly because the researchers were able to examine serious fracture outcomes in older and middle-aged adults with type 2 diabetes.
However, the findings do not prove that GLP-1 medicines prevent fractures. The research was retrospective and observational, meaning scientists looked back at existing medical records rather than randomly assigning people to different drugs. Patients who receive GLP-1 medicines may differ from those prescribed DPP-4 inhibitors in ways that could influence fracture risk.
For example, differences in body weight, physical activity, other medicines, health care use, or underlying health could affect the results even when researchers try to account for them. Electronic medical records can also contain incomplete information about lifestyle, falls, bone density, or medication use.
Another important question is what happens over longer periods. Three years provides useful information, but many people may use diabetes and weight-loss medicines for much longer. Researchers need to understand whether any apparent protection continues, disappears, or changes after many years of treatment.
Future prospective studies could follow patients from the beginning and collect detailed measurements of bone density, muscle mass, falls, nutrition, and physical activity.
Laboratory research may also help explain whether GLP-1 medicines have direct biological effects on bone. Such work would make it easier to determine whether the association seen in this study represents a true protective effect.
For now, the results provide encouraging evidence rather than a reason to prescribe GLP-1 drugs specifically for fracture prevention.
Treatment decisions should still consider blood sugar control, weight, cardiovascular health, side effects, costs, and each person’s medical needs. People taking these medicines should also continue to pay attention to exercise, nutrition, fall prevention, and other parts of healthy aging.
Overall, the study challenges concerns that GLP-1-related weight loss must necessarily translate into more serious fractures in people with type 2 diabetes. In this large group, the opposite pattern was observed. If future studies confirm the finding, protecting against fractures could become another important consideration when doctors choose diabetes treatments for older adults.
If you care about health, please read studies that plant-based diets can harm your bone health without these nutrients, and how to ease arthritis with anti-inflammatory foods.
For more health information, please see recent studies that too much of this vitamin may increase your risk of bone fractures, and results showing this type of exercise may protect your bone health, slow down bone aging.
Source: UCLA Health.
